PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Tuesday, June 11, 2013

Charles Nemeroff - Honoured in Britain, the US psychiatrist who took $1.2m from drug companies

Posted on 9:29 PM by Unknown

Britain’s premier institute for the study of mental illness has become embroiled in a damaging row over its decision to invite a disgraced US academic to give the inaugural lecture for a new research centre.

The decision by the Institute of Psychiatry at Kings College, in central London, Europe’s largest psychiatric research organisation, to invite Professor Charles Nemeroff, an expert in the treatment of depression, has split the psychiatric profession and been attacked by members of the institute itself. Professor Nemeroff, a leading authority on the biological causes of mental illness, is one of the highest profile doctors to have been exposed for concealing large payments from pharmaceutical companies.

He was forced to resign his post at Emory University, Atlanta, in 2008 after an investigation revealed that he had failed to report more than $1.2m of payments from GlaxoSmithKline, despite having signed an undertaking to limit payments to $10,000 a year.

He received the payments whilst undertaking a study on behalf of the National Institutes of Health into drugs made by GSK.

In 2009, Professor Nemeroff was appointed chair of psychiatry at the University of Miami and was subsequently awarded a research grant of $400,000 a year for the next five years by the National Institutes of Health. In 2012 it emerged that US Senator Charles Grassley, whose 2008 investigation triggered Professor Nemeroff’s  downfall, had written to the National Institutes of Health to ask why they had given him a grant when he was still under federal investigation.

Now a group of UK psychiatrists have written to the Institute of Psychiatry protesting against its decision to invite Professor Nemeroff to give the “inaugural annual lecture for the new Centre for Affective Disorders”, which is due to take place at the institute next Monday.

The group representing the radical Critical Psychiatry Network claims the Nemeroff case is frequently cited as “one of the starkest examples of the financial corruption of medicine” through its “overly cosy relationship with the pharmaceutical industry”.

“Many medical institutions have recognised this relationship is unhealthy and is bringing the profession into disrepute. We find it surprising therefore that the Institute of Psychiatry has seen fit to invite Nemeroff to deliver this important lecture,” they wrote.

Separately, Derek Summerfield, honorary senior lecturer at the Institute, wrote in the BMJ, formerly called the British Medical Journal, last week that the Institute of Psychiatry’s lauding of Professor Nemeroff as “one of the world’s leading experts” showed how psychiatric academe “sails blithely on as if such revelations beg no broader questions about its associations and supposed scientific independence.”

In a response, the Institute said it was “aware of the concerns” and took the issue of declaring financial conflicts of interest “extremely seriously”.

“We have been informed by Professor Nemeroff that he will not be presenting any research that was funded by commercial companies or affected by commercial implications. Obviously, he will be declaring any relevant conflicts of interest prior to his lecture.”

Professor Nemeroff could not be contacted for comment. He has previously said that his payments from GSK were for talks about GSK drugs now on the market, while his research funded by NIH involved basic laboratory studies of GSK chemical compounds that were years away from market.

http://www.independent.co.uk/life-style/health-and-families/health-news/

honoured-in-britain-the-us-psychiatrist-who-took-12m-from-drug-companies-8654535.html

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ►  July (104)
    • ▼  June (81)
      • China detains GlaxoSmithKline staff for fraud: rep...
      • Get in the sack
      • Tamiflu saga continues - NYT. By Katie Thomas
      • Gouging the patient - 1boringoldman explains
      • Deen dumped
      • FDA shuts down 1,677 online pharmacies
      • Treasure Ireland contd.
      • SEC charges medical imaging firm CEO for lying on ...
      • Sleepy Seroquel
      • Federal lawmakers urge FDA to change rules to allo...
      • #UMNProud
      • Nemeroff in London - let's see the slides
      • Pfizer still on the asbestos hook
      • Meet the new Mr NICE Guy
      • Of the 86 drugs in the industry's diabetes pipelin...
      • Sometimes it is best to do nothing. A "must read "...
      • Evidence Based Medicine - Why we can’t trust clini...
      • Pharmaceutical scandal: 'You pay us £300. However,...
      • SCANDAL
      • Who's who at Quantum Pharmaceuticals?
      • Busted! No Solace for Quantum
      • Saying no to chemotherapy by Des Spence - BMJ
      • For you - special price!
      • Zalcrap contd.
      • Your puny western ads don't work on our Russian wo...
      • UK plans to cut some drug prices by up to 20 per cent
      • A Fistful of Dollars - The Cephalon off label way
      • A Smoking Pillbox: Evidence that Sgt. Bales May Ha...
      • Nine pharmas fined by EU
      • Jagemeister PR - you're doing it wrong
      • For AZ's Onglyza SAVOUR is not a saviour
      • EU fines Lundbeck for paying off pharma rivals
      • Young Law Group Announces Initiative Prosecuting A...
      • FDA Probes Deaths Linked to Long-Acting Zyprexa
      • A holy mess
      • J&J buy Aragon
      • Introducing polypill.com - medication for the mass...
      • FT - Professor turns to internet to distribute pol...
      • Shire Pharmaceuticals Ltd and Roche Products Limit...
      • NIH Censoring Expert to Prevent Criticism of Ethic...
      • Merck announces it will slash jobs at research lab...
      • AllTrials - the countdown begins
      • Experts Propose Restoring Invisible And Abandoned ...
      • The Painful Politics of Painkillers Opioids are de...
      • GSK - Little Trouble in Big China
      • No dishonour in depression
      • Healing the Overwhelmed Physician - by Jerry Avorn
      • GlaxoSmithKline Fires China R&D Boss for 'Misrepre...
      • Charles Nemeroff - Honoured in Britain, the US psy...
      • How Big Pharma Drives Up Medicare Spending Without...
      • Walgreens pays record $80 million settlement for i...
      • Has pancreatic damage from glucagon suppressing di...
      • Austerity is bull!
      • Obama administration reverses course on Plan B pill
      • Corporate Whistle Blower Center Now Urges Pharmace...
      • Endo Implodes
      • Introducing OTC Toolbox
      • Pearl bought
      • Johnson & Johnson seeks home court advantage in Ty...
      • The geography of antidepressant, antipsychotic, an...
      • One to watch - Dispatches, Channel 4, Monday June ...
      • How much is your doctor making from Big Pharma?
      • Not just Bad - Ineffective Pharma!
      • Not just Bad - Filthy Pharma
      • Big data to sniff out drug marketing fraud
      • Dr Sidney Wolfe retires with a bang!
      • Kerching!
      • No-user, no cry
      • Nine pharma firms face EU fines over pay-for-delay...
      • Here for a good time or a long time?
      • Yet another J&J recall!
      • The Myth of the New
      • Keepy-uppy!
      • Meet the Doctor Big Pharma Can't Shut Up
      • In Memoriam: Barbara A. Brenner, 1951-2013
      • Pink Ribbons Inc. - watch the movie
      • Gouging 101 spotted by Dr Judy Stone
      • Summer Reading contd. Blood Medicine by Kathleen S...
      • Corporate fines are puny
      • "Brad Abbey" on Ben Goldacre
      • AllTrials contd. - D Day for comments - June 10th
    • ►  May (5)
Powered by Blogger.